Dunn Adam G, Zhou Xujuan, Hudgins Joel, Arachi Diana, Mandl Kenneth D, Coiera Enrico, Bourgeois Florence T
Centre for Health Informatics, Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales 2109, Australia.
Centre for Health Informatics, Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales 2109, Australia; School of Management and Enterprise, University of Southern Queensland, Toowoomba, Queensland 4350, Australia.
J Clin Epidemiol. 2016 Dec;80:43-49. doi: 10.1016/j.jclinepi.2016.07.010. Epub 2016 Jul 25.
To characterize the conclusions and production of nonsystematic reviews about neuraminidase inhibitors relative to financial competing interests held by the authors.
We searched for articles about neuraminidase inhibitors and influenza (January 2005 to April 2015), identifying nonsystematic reviews and grading them according to the favorable/nonfavorable presentation of evidence on safety and efficacy. We recorded financial competing interests disclosed in the reviews and from other articles written by their authors. We measured associations between competing interests, author productivity, and conclusions.
Among 213 nonsystematic reviews, 138 (65%) presented favorable conclusions. Financial competing interests were identified for 26% (137/532) of authors; 51% (108/213) of reviews were associated with a financial competing interest. Reviews produced exclusively by authors with financial competing interests (33%; 71/213) were more likely to present favorable conclusions than reviews with no competing interests (risk ratio 1.27; 95% confidence interval 1.03-1.55). Authors with financial competing interests published more articles about neuraminidase inhibitors than their counterparts.
Half of nonsystematic reviews about neuraminidase inhibitors included an author with a financial competing interest. Reviews produced exclusively by these authors were more likely to present favorable conclusions, and authors with financial competing interests published a greater number of reviews.
描述关于神经氨酸酶抑制剂的非系统性综述的结论及产出与作者的财务利益冲突之间的关系。
我们检索了关于神经氨酸酶抑制剂和流感的文章(2005年1月至2015年4月),识别非系统性综述并根据其对安全性和有效性证据的支持/不支持程度进行分级。我们记录了综述中披露的以及其作者撰写的其他文章中披露的财务利益冲突。我们衡量了利益冲突、作者产出和结论之间的关联。
在213篇非系统性综述中,138篇(65%)得出了支持性结论。26%(137/532)的作者存在财务利益冲突;51%(108/213)的综述与财务利益冲突相关。仅由存在财务利益冲突的作者撰写的综述(33%;71/213)比无利益冲突的综述更有可能得出支持性结论(风险比1.27;95%置信区间1.03 - 1.55)。存在财务利益冲突的作者发表的关于神经氨酸酶抑制剂的文章比其同行更多。
关于神经氨酸酶抑制剂的非系统性综述中有一半包含存在财务利益冲突的作者。仅由这些作者撰写的综述更有可能得出支持性结论,且存在财务利益冲突的作者发表的综述数量更多。